诺泰生物：两款产品获得药品注册证书

Core Viewpoint - The approval of injectable Acetate Cetrorelix and Agomelatine tablets by the National Medical Products Administration marks a significant advancement for the company in the reproductive and mental health sectors, aligning with national policies aimed at enhancing population quality and healthcare accessibility [1][2]. Group 1: Product Approvals - The injectable Acetate Cetrorelix is a third-generation GnRH antagonist that offers unique clinical advantages in assisted reproductive technology compared to other similar drugs, such as GnRH agonists and other antagonists like Ganirelix [1]. - Acetate Cetrorelix demonstrates superior onset speed, safety (prevention of OHSS), shorter treatment cycles, and better patient tolerance compared to GnRH agonists, and has milder injection reactions compared to other antagonists [1]. - Agomelatine is a novel antidepressant with a unique dual mechanism of action, distinguishing it from common antidepressants like SSRIs and SNRIs, and is the only antidepressant that improves sleep quickly without affecting daytime functioning [1]. Group 2: Market Position and Strategic Alignment - Agomelatine has a very low risk of sexual dysfunction, minimal impact on weight, good tolerance, and fewer withdrawal reactions, making it significant in the market for depression accompanied by insomnia [1]. - The successful approval of these products represents the company's strategic expansion into reproductive and mental health, complementing existing antiviral, cardiovascular, and immune regulation product lines [2]. - This expansion aligns with national policies on childcare subsidies and the inclusion of assisted reproduction in health insurance, providing strong support for patient services and contributing to the high-quality development of the national population [2].